Clinical Trials Using Dactinomycin

Clinical trials are research studies that involve people. The clinical trials on this list are studying Dactinomycin. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma

    This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy or combination chemotherapy plus temsirolimus is more effective in treating patients with intermediate-risk rhabdomyosarcoma.
    Location: 291 locations

  • Evolutionary Inspired Therapy for the Treatment of Fusion Positive Newly Diagnosed or Metastatic Rhabdomyosarcoma

    This phase II trial investigates evolutionary inspired therapy in treating fusion positive rhabdomyosarcoma that is newly diagnosed or has spread to other places in the body (metastatic). Chemotherapy drugs, such as vinorelbine, vincristine sulfate, and actinomycin D, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is used to decrease the body's immune response and may inhibit DNA replication and initiate cell death. This study is being done to determine which of 4 different therapeutic treatments will have the best chance of the disease not worsening or coming back.
    Location: Moffitt Cancer Center, Tampa, Florida

  • A Study of Pembrolizumab plus Local Chemotherapy using Isolated Limb Infusion (ILI) for Patients with Sarcoma in the Arm or Leg

    This phase II trial studies how well pembrolizumab and chemotherapy delivered via isolated limb infusion works in treating patients with sarcoma of the arm or leg that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as melphalan and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Isolated limb infusion delivers chemotherapy to the affected arm or leg. Giving pembrolizumab and isolated limb infusion with melphalan and dactinomycin into the affected arm or leg may delay the time before the disease gets worse (progresses).
    Location: Memorial Sloan Kettering Cancer Center, New York, New York